PLCG1 mutations in cutaneous T-cell lymphomas

Abstract

Key Points• Activating mutations in PLCG1 are a frequent finding in tumoral CTCL samples. This raises the possibility of targeted therapies against PLCG1 signaling pathway, using calcineurin inhibitors.Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of primary cutaneous T-cell lymphoproliferative processes, mainly composed of mycosis fungoides and Sézary syndrome, the aggressive forms of which lack an effective treatment. The molecular pathogenesis of CTCL is largely unknown, although neoplastic cells show increased signaling from T-cell receptors (TCRs). DNAs from 11 patients with CTCL, both normal and tumoral, were target-enriched and sequenced by massive parallel sequencing for a selection of 524 TCR-signaling-related genes. Identified variants were validated by capillary sequencing. Multiple mutations were found that affected several signaling pathways, such as TCRs, nuclear factor kB, or Janus kinase/signal transducer and activator of transcription, but PLCG1 was found to be mutated in 3 samples, 2 of which featured a redundant mutation (c.1034T>C, S345F) in exon 11 that affects the PLCx protein catalytic domain. This mutation was further analyzed by quantitative polymerase chain reaction genotyping in a new cohort of 42 patients with CTCL, where it was found in 19% of samples. Immunohistochemical analysis for nuclear factor of activated T cells (NFAT) showed that PLCG1-mutated cases exhibited strong NFAT nuclear immunostaining. Functional studies demonstrated that PLCG1 mutants elicited increased downstream signaling toward NFAT activation, and inhibition of this pathway resulted in reduced CTCL cell proliferation and cell viability. Thus, increased proliferative and survival mechanisms in CTCL may partially depend on the acquisition of somatic mutations in PLCG1 and other genes that are essential for normal T-cell differentiation. (Blood. 2014;123(13):2034-2043

Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma

“…1 As part of our findings we detected a number of mutations potentially affecting JAK/STAT signaling. These findings were recently confirmed by an independent group, suggesting that mutations in this pathway may contribute as disease mechanisms in CTCL.…”

Cool-temperature-mediated activation of phospholipase C-γ 2 in the human hereditary disease PLAID

“…Thus, point mutations in the human PLCG1 gene have been linked to secondary, radiation-associated angiosarcoma [13] and to cutaneous T cell lymphoma [14]. Two mouse models of autoimmunity and autoinflammation, designated Ali5 and Ali14, have been described, which are caused by gain-of-function point mutations of PLC 2 , D 993 G and Y…”

RUbioSeq+: A multiplatform application that executes parallelized pipelines to analyse next-generation sequencing data

“…Our software implements pipelines for the analysis of SNVssingle nucleotide, indels, copynumber variation, bisulfite-seq and ChIP-seq experiments using well-established tools to perform these common tasks. The results obtained by RUbioSeq+ have already been validated and published (25,26). Moreover, RUbioSeq+ comes with a new and accessible GUI enabling researchers without advanced bioinformatics skills to straightforwardly manage complex NGS workflows.…”